Immunogenicity of biotherapeutics - An overview

Journal of Immunotoxicology

Volumn 3, Issue 3, 2006, Pages 151-156

  Subramanyam, Meena ^a  

^a BIOGEN   (United States)

Author keywords

Clinical sequelae; Contributing factors; Immunogenicity; Non clinical studies; Risk assessment; Therapeutic proteins

Indexed keywords

DRUG ANTIBODY; MONOCLONAL ANTIBODY;

CLINICAL PRACTICE; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG SAFETY; EXPERIENCE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; MEDIATOR RELEASE; PRIORITY JOURNAL; PROTEIN PURIFICATION; RISK ASSESSMENT;

EID: 33747600689     PISSN: 1547691X     EISSN: 1547691X     Source Type: Journal    
DOI: 10.1080/15476910600845740     Document Type: Conference Paper

References (47)

1. Amalfitano, A., Bengur, A. R., Morse, R. P., Majure, J. M., Case, L. E., Veerling D. L., Mackey, J., Kishnani, P., Smith, W., McVie-Wylie, A., Sullivan, J. A., Hoganson, G. E., Phillips, J. A., 3rd, Schaefer, G. B., Charrow, J., Ware, R. E., Bossen, E. H., and Chen, Y. T. 2001. Recombinant human acid ́-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial. Genet. Med. 3:132-138.
2. Bertolotto, A., Gilli, F., Sala, A., Capobianco, M., Malucchi, S., Milano, E., Melis, F., Marnetto, F., Lindberg, R. L., Bottero, R., Di Sapio, A., and Giordana, M. T. 2003. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology 60:634-639.
3. Braun, A., Kwee, L., Labow, M. A., and Alsenz, J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. Oct;14(10):1472-1478.
4. Cariappa, R., Tang, M., Parng, C., Nebelitskiy, E., Carroll, M., Georgopoulos, K., and Pillai, S. 2001. The follicular versus marginal zone B-lymphocyte cell fate decision is regulated by Aiolos, BTK, and CD21. Immunity 14:603-615.
5. Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J. J., Martin-DuPont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., Varet, B., and Mayeux, P. 2002. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N. Eng. J. Med. 346:469-475.
6. Chance, R. E., Root, M. A., and Galloway, J. A. 1976. The immunogenicity of insulin preprations. Acta. Endocrinol. Suppl. 205:185-198.
7. Christen, U., Thuerkauf, R., Stevens, R., and Leaalauer, W. 1999. Immune response to a recombinant human TNFR55-IgG1 fusion protein: Autoantibodies in rheumatoid arthritis and multiple sclerosis patients have neither neutralizing nor agonist activities. Human Immunol. 60:774-790.
8. Clark, M. R., Massenburg, D., Siemasko, K., Hou, P., and Zhang, M. 2004. B-Cell antigen receptor signaling requirements for targeting antigen to the MHC Class II presentation pathway. Curr. Opin. Immunol. 16:382-387.
9. Colowick, A. B. Bohn, R. L., Avorn, J., and Ewenstein, B. M. 2000. Immune tolerance induction in hemophilia patients with inhibitors: Costly can be cheaper. Blood 96:1698-1702.
10. Coscarella, A., Liddi, R., Di, L. M., Bach, S., Faiella, A., van der Meide, P. H., Mele, A., and De Santis, R. 1998. The rhGM-CSF-EPO hybrid protein MEN11300 induces anti-EPO antibodies and severe anemia in rhesus monkeys. Cytokine 10:964-969.
11. Finkelman, F. D., Madden, K., Morris, S., Holmes, J., Boiani, N., Katona, I., and Maliszewski, C. R. 1993. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine anti cytokine antibody complexes. J. Immunol. 151:1235-1244.
12. Gallegos, A. M., and Bevan, M. J. 2006. Central tolerance. Good but imperfect. Immunol. Rev. 209:290-296.
13. Goodnow, C. C. 1992. Transgenic mice and analysis of B-cell tolerance. Ann. Rev. Immunol. 10:489-518.
14. Hanauer, S. B. 1999. Review article: Safety of infliximab in clinical trials. Aliment. Pharmacol. Ther. 13:16-22.
15. Hardy, L., Rogers, B., Thomas, D., Ryan, A., Peterson, M., and Koren, E. 1997. Toxicologist 36:277.
16. Haribhai, D., Engle, D., Meyer, M., Donermeyer, D., White, J. M., and Williams, C. 2003. A threshold for central T-cell tolerance to an inducible serum protein. J. Immunol. 170:3007-3014.
17. Hermeling, S., Jiskoot, W., Crommelin, D., Bornaes, C., and Schellekens, H. 2005. Development of a transgenic mouse model immune tolerant for human interferon Beta. Pharm. Res. 22:847-851.
18. Huseby, E. S., White, J., Crawford, F., Vass, T., Becker, D., Pinilla, C., Marrack, P., and Kappler, J. W. 2005. How the T-cell repertoire becomes peptide and MHC specific. Cell 122:247-260.
19. International Conference on Harmonisation: Preclinical safety evaluation of biotechnology-derived pharmaceuticals. 1997. ICH topic S6 Guidance. (ICH guidelines are available from the website 〈http://www.eudra.org/emea. html〉, CPMP/ICH/302/95).
20. LaRocca, A. P., Leung, S. C., Marcus, S. G., Colby C. B., and Borden, E. C. 1989. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-β ser. J. Interferon Res. 9(S1):S51-S60.
21. Li, J., Yang, C., Yuping, X., Bertino, A., Glaspy, J., Roberts, M., and Kuter, D. J. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241-3248.
22. Masa, G., Vanderschueren-Lodeweyckc, M., and Bouillon, R. 1993. Five-year follow up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. Clin. Endocrinol. 38:137-142.
23. Mayeux, P., and Casadevall, N. 2003. Antibodies to endogenous and recombinant erythropoietin. In: Erythropoietins and Erythropoiseis, eds. G. Molineux, M.A. Fotte, and S.G. Elliot, pp. 229-239. Switzerland: Birkhauser Verlag.
24. Mire-Sluis A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S. J., Taniguchi, G., Wierda, D., and Zuckerman, L. A. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Meth. 289:1-16.
25. Moore,W. V., and Leppert, P. 1980. Role of aggregated growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51:691-697.
26. Piercy, R., Swardson, C., and Hinchcliff, K. 1998. Erythroid hypoplasia and anemia following administration of recombinant human erythropoietin in two horses. J. Am. Vet. Med. Assoc. 212:244-247.
27. Ragnhammar, P., Friesen, H. J., Frodin, J. E., Lefvert, A. K., hassan, M., Osterborg, A., and Mellstedt, H. 1994. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in non-immunocompromised patients. Blood 84:4078-4087.
28. Reeves, W. G., Barr, D., Douglas, C. A., Gelsthorpe, K., Hanning, I., Skene, A., Wells, L., Wilson, R. M., and Tattersall, R. B. 1984a. Factors governing the human immune response to injected insulin. Diabetologia 26:266-271.
29. Reeves, W. G., Gelsthorpe, K., Van der Minne, P., Torensma, R., and Tattersall, R. B. 1984b. HLA phenotype and insulin antibody production. Clin. Exp. Immunol. 57:443-448.
30. Reth, M. 1992. Antigen receptors on B-lymphocytes. Ann. Rev. Immunol. 10:97-121.
31. Revoltella, R. 1998. Natural and therapeutically induced antibodies to cytokines. Biotherapy 10:321-331.
32. Rolink, A. G., Schaniel, C., Andersson, J., and Melchers, F. 2001. Selection events operating at various stages in B-cell development. Curr. Opin. Immunol. 13:202-207.
33. Rosenschein, U., Lenz, R., Radnay, J., Tovim, T., and Rozenszajn, L. A. 1991. Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction. Isr. J. Med. Sci. 27:541-545.
34. Saint-Remy, J. M. 2002. Immunology of factor VIII inhibitors. Sem. Thromb. Hemost. 28:265-268.
35. Santori, F. R., and Vukmanovic, S. 2004. Delineation of signals required for thymocyte positive selection. J. Immunol. 173:5517-5523.
36. Scandella, D. 2002. New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to Factor VIII. Sem. Thromb. Hemost. 28:291-296.
37. Scharenberg, J. G., Stam, A. G., von Blomberg, B. M., Roest, G. J., Palmer, P. A., Franks, C. R., Meijer, C. J., and Scheper, R. J. 1994. The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2 Eur. J. Cancer 12:1804-1809.
38. Schellekens H. 2005. Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract. Res. Clin. Haematol. 18:473-480.
39. Schwaab, R., Brackman, H. H., and Meyer, C. 1995. Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb. Haemost. 74:1402-1406.
40. Steis, R., and Longo, D. 1994. Clinical relevance of recombinant interferon alpha-2a antibodies in patients with hairy cell leukemia. J. Interferon Res. 14:207-209.
41. Steis, R., Smith, J. W., Urba, W. J., Clark, J. W., Itri, L. M., Evans, L. M., Schoenberger, C., and Longo, D. 1988. Resistance to recombinant interferon alpha-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318:1409-1413.
42. Tiberio, L., Caruso, A., Pozzi, A., Rivoltini, L., Morelli, D., Monti, E., and Balsari, A. 1993. The detection and biological activity of human antibodies to IL-2 in normal donors. Scand. J. Immunol. 38:472-476.
43. Tuddenhamn, E. G., and McVey, J. H. 1998. Genetic basis of inhibitor development in haemophilia A. Haemophilia 4:543-545.
44. Van Haeften, T. W. 1989. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetic Care 12:641-648.
45. Wadhwa, M., Skog, A. L., Bird, C., Ragnhammar, P., Lilljefors, M., Gaines-Das, R., Mellstedt, H., and Thorpe, R. 1999. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res. 5:1353-1361.
46. Wadhwa, M., Bird, C., Dilger, P., Gaines-Das, R., and Thorpe, R. 2003. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Meth. 278:1-17.
47. Whittingham, S., and Mackey, I. R. 1976. Adverse reactions to drugs: Relationship to immunopathic disease. Med. J. Austral. 1:486-488, 490-492.